CDK4 and plasma cell myeloma: We identify a novel dual-targeting c-Myc inhibitor D347-2761 targeting c-Myc unstable domain and c-Myc/Max heterodimerization, which further inhibits myeloma growth and infiltration in vitro and in vivo via regulating downstream CDK4 promoter transcriptional activity.